The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial
Open accessAbstract
No effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage, death, or long-term functional disability in survivors require clinical evaluation. We performed a parallel assigned controlled, non-randomized, phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease. The study enrolled 18 hospitalized patients with COVID-19 (n = 9 for each group). The treatment group received three cycles of intravenous infusion of UC-MSCs (3 × 10 7 cells per infusion) on days 0, 3, and 6. Both groups received standard COVID-treatment regimens. Adverse events, duration of clinical symptoms, laboratory parameters, length of hospitalization, serial chest computed tomography (CT) images, the PaO 2/FiO 2 ratio, dynamics of cytokines, and IgG and IgM anti-SARS-CoV-2 antibodies were analyzed. No serious UC-MSCs infusion-associated adverse events were observed. Two patients receiving UC-MSCs developed transient facial flushing and fever, and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion. Mechanical ventilation was required in one patient in the treatment group compared with four in the control group. All patients recovered and were discharged. Our data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated. Phase 2/3 randomized, controlled, double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC-MSCs to reduce deaths and improve long-term treatment outcomes in patients with serious COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Self-citationTang, N., Li, D., Wang, X., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14768 · Cited by 5,662
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819
SARS-CoV-2 and viral sepsis: observations and hypotheses
Li, H., Liu, L., Zhang, D., Xu, J., Dai, H., Tang, N., Su, X., & Cao, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30920-x · Cited by 1,178
Self-citationLeng, Z., Zhu, R., Hou, W., Feng, Y., Yang, Y., Han, Q., Shan, G., Meng, F., Du, D., Wang, S., et al. (2020) · Aging and disease · doi:10.14336/ad.2020.0228 · Cited by 1,147
Self-citationMesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial
Wilson, J. G., Liu, K. D., Zhuo, H., Caballero, L., McMillan, M., Fang, X., Cosgrove, K., Vojnik, R., Calfee, C. S., Lee, J.-W., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70291-7 · Cited by 759
Cited by
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Lanzoni, G., Linetsky, E., Correa, D., Messinger Cayetano, S., Alvarez, R. A., Kouroupis, D., Alvarez Gil, A., Poggioli, R., Ruiz, P., Marttos, A. C., et al. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0472 · Cited by 404
Shi, L., Huang, H., Lu, X., Yan, X., Jiang, X., Xu, R., Wang, S., Zhang, C., Yuan, X., Xu, Z., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00488-5 · Cited by 283
Self-citationDabrowska, S., Andrzejewska, A., Janowski, M., & Lukomska, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591065 · Cited by 282
Mazini, L., Ezzoubi, M., & Malka, G. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02006-w · Cited by 267
Metadata
- Authors
- Meng, F., Xu, R., Wang, S., Xu, Z., Zhang, C., Li, Y., Yang, T., Shi, L., Fu, J., Jiang, T., Huang, L., Zhao, P., Yuan, X., Fan, X., Zhang, J.-Y., Song, J., Zhang, D., Jiao, Y., Liu, L., Zhou, C., Maeurer, M., Zumla, A., Shi, M., & Wang, F.-S.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2020-08-27
- Volume
- 5
- Issue
- 1
- Pages
- 172-172
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W3080114020
- Cited by
- 323
- References
- 29
- FWCI
- 29.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. https://app.cochat.ai/papers/10.1038/s41392-020-00286-5
- The paper
- Meng, F., Xu, R., Wang, S., Xu, Z., Zhang, C., Li, Y., Yang, T., Shi, L., Fu, J., Jiang, T., Huang, L., Zhao, P., Yuan, X., Fan, X., Zhang, J.-Y., Song, J., Zhang, D., Jiao, Y., Liu, L., . . . Wang, F.-S. (2020). Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-020-00286-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
